Recent performance snapshot

Twist Bioscience (TWST) has drawn fresh attention in early June as investors reassess the stock after a strong year to date move. The share price last closed at $67.86.

The company now carries a market value of about $4.16b, with reported annual revenue of $409.479 million and a net loss of $81.276 million. This is setting the stage for closer scrutiny of its growth profile and risks.

Beyond the latest move, Twist Bioscience has been on a strong run, with a year-to-date share price return of 109.51% and a 1-year total shareholder return of 118.45%. This points to strong momentum supported by a very large 3-year total shareholder return of 319.15%, even though the 5-year total shareholder return has declined 33.32%.

If you are looking for other fast-changing opportunities in related areas like biotech tools and data-driven therapeutics, it could be worth scanning 40 healthcare AI stocks

With the stock up sharply over the past year, trading slightly above the average analyst price target of US$64.44, you now need to ask: is Twist Bioscience undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 7.1% Overvalued

With Twist Bioscience last closing at $67.86 against a widely followed fair value estimate of about $63.33, the most popular narrative sees the stock trading ahead of that modeled level and leans heavily on long term earnings potential to justify its stance.

Significant improvements in gross margin (now above 50%) through volume leverage, process improvements, and increased vertical integration signal ongoing margin expansion and a clear near-term path toward adjusted EBITDA breakeven, indicating robust future earnings potential.

Want to see what sits behind that confidence in future earnings power? The narrative leans on steady revenue expansion, rising margins and a rich future earnings multiple that is usually reserved for market favorites.

Result: Fair Value of $63.33 (OVERVALUED)

However, there is still meaningful execution risk, with ongoing losses and heavy reliance on a small group of NGS customers, which could unsettle revenue and sentiment.

Next Steps

With sentiment clearly mixed, this is the moment to review the underlying data yourself and decide quickly how to shape your own view using 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If you stop here, you risk missing other stocks that could suit your goals, so keep building your watchlist with focused, data driven ideas.

• Target stronger long term value potential by scanning 47 high quality undervalued stocks that combine fundamentals with attractive pricing.
• Prioritise resilience in your portfolio by reviewing 62 resilient stocks with low risk scores that score well on stability and downside protection.
• Get ahead of the crowd by checking the screener containing 22 high quality undiscovered gems that still fly under most investors' radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.